These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 29741421

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. STAT3 Activation Is Associated with Interleukin-10 Expression and Survival in Primary Central Nervous System Lymphoma.
    Yang X, Wang Y, Sun X, Bai X, Cui Q, Zhu H, Qian J, Chen Y, Sun S, Ji N, Liu Y.
    World Neurosurg; 2020 Feb; 134():e1077-e1084. PubMed ID: 31778838
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. New approaches in primary central nervous system lymphoma.
    Fraser E, Gruenberg K, Rubenstein JL.
    Chin Clin Oncol; 2015 Mar; 4(1):11. PubMed ID: 25841718
    [Abstract] [Full Text] [Related]

  • 8. The role of upfront autologous stem cell transplantation in high-risk younger patients with primary central nervous system lymphoma.
    Cho H, Chang JH, Kim YR, Kim SJ, Chung H, Park H, Lee JY, Jang JE, Kim Y, Kim SH, Yang WI, Suh CO, Cheong JW, Min YH, Kim JS.
    Br J Haematol; 2016 Aug; 174(3):444-53. PubMed ID: 27018207
    [Abstract] [Full Text] [Related]

  • 9. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.
    Mappa S, Marturano E, Licata G, Frezzato M, Frungillo N, Ilariucci F, Stelitano C, Ferrari A, Sorarù M, Vianello F, Baldini L, Proserpio I, Foppoli M, Assanelli A, Reni M, Caligaris-Cappio F, Ferreri AJ.
    Hematol Oncol; 2013 Sep; 31(3):143-50. PubMed ID: 23161567
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Therapeutic management of refractory or relapsed primary central nervous system lymphomas.
    Reni M, Ferreri AJ.
    Ann Hematol; 2001 Sep; 80 Suppl 3():B113-7. PubMed ID: 11757691
    [Abstract] [Full Text] [Related]

  • 12. Thiotepa, busulfan, and cyclophosphamide or busulfan, cyclophosphamide, and etoposide high-dose chemotherapy followed by autologous stem cell transplantation for consolidation of primary central nervous system lymphoma.
    Hyung J, Hong JY, Yoon DH, Kim S, Park JS, Park CS, Lee SW, Kim JH, Ryu JS, Huh J, Suh C.
    Ann Hematol; 2019 Jul; 98(7):1657-1664. PubMed ID: 30989325
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for patients with primary central nervous system lymphoma in first complete remission.
    DeFilipp Z, Li S, El-Jawahri A, Armand P, Nayak L, Wang N, Batchelor TT, Chen YB.
    Cancer; 2017 Aug 15; 123(16):3073-3079. PubMed ID: 28369839
    [Abstract] [Full Text] [Related]

  • 15. A prospective phase II trial of response adapted whole brain radiotherapy after high dose methotrexate based chemotherapy in patients with newly diagnosed primary central nervous system lymphoma-analysis of acute toxicity profile and early clinical outcome.
    Adhikari N, Biswas A, Gogia A, Sahoo RK, Garg A, Nehra A, Sharma MC, Bhasker S, Singh M, Sreenivas V, Chawla R, Joshi G, Kumar L, Chander S.
    J Neurooncol; 2018 Aug 15; 139(1):153-166. PubMed ID: 29633112
    [Abstract] [Full Text] [Related]

  • 16. Central Nervous System Lymphoma: Approach to Diagnosis and Treatment.
    Correia CE, Schaff LR, Grommes C.
    Cancer J; 2020 Aug 15; 26(3):241-252. PubMed ID: 32496457
    [Abstract] [Full Text] [Related]

  • 17. A Rare Case of Primary Central Nervous System Lymphoma in an Adolescent Female Treated with High-Dose Methotrexate and Rituximab-Based Chemoimmunotherapy and Consolidation Whole Brain Radiotherapy.
    Biswas A, Adhikari N, Bakhshi S, Gopinathan VR, Sharma MC.
    Pediatr Neurosurg; 2019 Aug 15; 54(1):57-65. PubMed ID: 30669145
    [Abstract] [Full Text] [Related]

  • 18. Promising treatment results with blood brain barrier disruption (BBBD) based immunochemotherapy combined with autologous stem cell transplantation (ASCT) in patients with primary central nervous system lymphoma (PCNSL).
    Kuitunen H, Tokola S, Siniluoto T, Isokangas M, Sonkajärvi E, Alahuhta S, Turpeenniemi-Hujanen T, Jantunen E, Nousiainen T, Vasala K, Kuittinen O.
    J Neurooncol; 2017 Jan 15; 131(2):293-300. PubMed ID: 27752883
    [Abstract] [Full Text] [Related]

  • 19. A new prognostic score for disease progression and mortality in patients with newly diagnosed primary CNS lymphoma.
    Liu CJ, Lin SY, Yang CF, Yeh CM, Kuan AS, Wang HY, Tsai CK, Gau JP, Hsiao LT, Chen PM, Liu YC, Hong YC, Ko PS, Liu JH, Lin CH.
    Cancer Med; 2020 Mar 15; 9(6):2134-2145. PubMed ID: 32011103
    [Abstract] [Full Text] [Related]

  • 20. Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network.
    Langner-Lemercier S, Houillier C, Soussain C, Ghesquières H, Chinot O, Taillandier L, Soubeyran P, Lamy T, Morschhauser F, Benouaich-Amiel A, Ahle G, Moles-Moreau MP, Moluçon-Chabrot C, Bourquard P, Damaj G, Jardin F, Larrieu D, Gyan E, Gressin R, Jaccard A, Choquet S, Brion A, Casasnovas O, Colin P, Reman O, Tempescul A, Marolleau JP, Fabbro M, Naudet F, Hoang-Xuan K, Houot R.
    Neuro Oncol; 2016 Sep 15; 18(9):1297-303. PubMed ID: 26951382
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.